Sublingual Immunotherapy May Result in Desensitization and Remission for Peanut-Allergic Children
MILWAUKEE, Oct. 10, 2023 /PRNewswire-PRWeb/ -- Peanut sublingual immunotherapy (SLIT) is safe for young children and results in a greater likelihood of desensitization and remission, according to new research published in The Journal of Allergy and Clinical Immunology (JACI), an official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI).
- 60% of peanut-allergic children in the test group experience desensitization to peanut protein after sublingual immunotherapy according to research from JACI, an official journal of the AAAAI.
- Upon assessment, 60% of children in the study were found to experience desensitization to peanut protein, and 48% experienced remission three months after therapy.
- Conducted over a 36-month period, the double-blind, placebo-controlled study assessed the effectiveness of peanut sublingual immunotherapy (SLIT) on 50 children aged 1- to 4 years old.
- Upon assessment, 60% of children in the study were found to experience desensitization to peanut protein, and 48% experienced remission three months after therapy.